Decoy Therapeutics Inc. entered a material agreement; sold unregistered shares; made a public disclosure
SEC 8-KRead source ↗
Decoy Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 1 selling2 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
The Fundamentalytics view
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Decoy Therapeutics Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 162% and a beta of 2.1 against the S&P 500.
Latest results
- Share reaction
- -19.5% in the first session after the results on July 31, 2025, against -2.0% for the S&P 500
Price chart
- 1 day-3.3%
- 1 week+12.5%
- 1 month-41.5%
- This year-86.7%
- 1 year-97.8%
- 5 years-100.0%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- July 31, 2025
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Agreement
- Shareholder vote
Decoy Therapeutics Inc. reported shareholder vote results
SEC 8-KRead source ↗ - Shareholder vote
Decoy Therapeutics Inc. reported shareholder vote results
SEC 8-KRead source ↗
No model value for Decoy Therapeutics Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Decoy Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.03 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Decoy Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$8.96 | +93% | — | — |
| Next | −$8.28 | +8% | — | — |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Mar 2026 | −$4.08 | −$4.18 | −2.5% |
| Dec 2025 | −$6.48 | $43.10 | +765.1% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 4.1% of tradable shares
- Days to cover
- 0.02 at average volume
- Short interest, 1 month
- +823% to October 15, 2026
- Held by institutions
- 3% of shares
- Held by insiders
- 2.9% of shares
- Employees
- 11 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| DCOY | −46% | −88% | −58% | −65% | −98% | −87% |
| Industry peers (median) | −35% | −56% | −17% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| DCOY | 25% | 17% | 25% | 33% | 33% | 18% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| DCOY | −84% | −92% | −84% | −78% | −99% | −94% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from June 1, 2016 to October 26, 2026. Getting back needed a 1287391204% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.92 – $43.44
- From 52-week high
- −97.6%
- vs 50-day average
- −51.1%
- vs 200-day average
- −81.0%
- Volatility (1 year)
- 162%
- Beta vs S&P 500
- 2.08
Share price after results
- Next day
- 4 up, 8 down typical move ±8.5%
- After a week
- 6 up, 6 down typical move ±11.9%
- After a month
- 5 up, 7 down typical move ±21.2%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| July 31, 2025 | −19.5% | −2.0% | −29.0% | −51.0% |
| January 17, 2025 | −5.3% | +1.9% | −6.1% | −45.8% |
| August 10, 2023 | −14.7% | 0.0% | +15.7% | +10.5% |
| November 10, 2022 | +2.2% | +6.5% | +7.6% | +2.2% |
| August 15, 2022 | −3.4% | +0.6% | −11.8% | −13.0% |
| May 12, 2022 | +17.5% | +2.3% | +23.1% | +21.9% |
| March 10, 2022 | −2.1% | −1.7% | +4.3% | −0.8% |
| August 5, 2021 | +7.7% | +0.8% | +10.9% | +42.1% |
| May 12, 2021 | +1.7% | −0.9% | +13.3% | −2.5% |
| November 12, 2020 | −4.5% | +0.4% | −8.1% | +14.3% |
| August 12, 2020 | −8.9% | +1.2% | −8.9% | −24.7% |
| July 29, 2020 | −14.5% | +0.9% | −3.8% | −26.0% |
Fundamentals
Who owns it
- Reported value
- $31,039
- Institutions reporting
- 4
- Shares held vs prior quarter
- ▲ 168.3%
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Vanguard Capital Management LLC | $29,004 | 4K | 93.4% | New |
| Tower Research Capital LLC (TRC) | $1,841 | 0K | 5.9% | ▼ 74.9% |
| UBS Group AG | $180 | 0K | 0.6% | ▼ 95.4% |
| Caitong International Asset Management Co., Ltd | $14 | 0K | 0.0% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Decoy Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $19,750 2 trades by 2 insiders, last 12 months Insider sales History → $17 2 trades by 1 insider · 0% under pre-set plans
Net ▲ $19,733 net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Hanish Arnold C Director | December 30, 2025 | Sell | 12 | $0.64 | $8 |
| Hanish Arnold C Director | December 30, 2025 | Sell | 15 | $0.64 | $10 |
| Rosenblum Mark J Exec VP Finance, CFO | November 20, 2025 | Buy | 20,000 | $0.80 | $16,000 |
| Hanish Arnold C Director | November 20, 2025 | Buy | 5,000 | $0.75 | $3,750 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- July 31, 2025
- January 17, 2025
- August 10, 2023
- November 10, 2022
- August 15, 2022
- May 12, 2022
Recent SEC filings
- S-1 S-1
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- DEF 14A Proxy statement
- 8-K Current report
- S-1 S-1
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Decoy Therapeutics Inc. in brief
- What does Decoy Therapeutics Inc. do?
- Decoy Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Decoy Therapeutics Inc.'s stock ticker?
- Decoy Therapeutics Inc. trades under the ticker DCOY on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Decoy Therapeutics Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Tower Research Capital LLC (TRC) and UBS Group AG. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Decoy Therapeutics Inc. stock?
- Over the last 12 months, Decoy Therapeutics Inc.'s directors and officers reported 2 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
Follow research on Decoy Therapeutics Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.